Scarica l'app Stockscreener
27.96
3.79%
1.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.94
Aprire:
$27.17
Volume 24 ore:
1.89M
Relative Volume:
1.03
Capitalizzazione di mercato:
$4.46B
Reddito:
$616.29M
Utile/perdita netta:
$447.18M
Rapporto P/E:
10.07
EPS:
2.7771
Flusso di cassa netto:
$-24.99M
1 W Prestazione:
-4.48%
1M Prestazione:
-1.89%
6M Prestazione:
-13.06%
1 anno Prestazione:
-24.55%
Intervallo 1D:
$26.93
$27.99
Intervallo di 1 settimana:
$26.76
$29.54
Portata 52W:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
27.96 | 4.46B | 616.29M | 447.18M | -24.99M | 2.7771 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis - simplywall.st
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
The Bull Case For TG Therapeutics (TGTX) Could Change Following New Azer-cel Milestone In Progressive MS - Sahm
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz
TGTX (TG Therapeutics) Total Assets : $1,063.3 Mil (As of Dec. 2025) - GuruFocus
Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir
TG Therapeutics to present BRIUMVI data at neurology meeting By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky - MarketBeat
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - The Manila Times
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Yahoo Finance
HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - simplywall.st
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 - Finviz
TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives - Sahm
TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap - Sahm
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - The Globe and Mail
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
TG THERAPEUTICS, INC. SEC 10-K Report - TradingView
TG Therapeutics: "Strong Buy" On BRIUMVI's Massive Growth And Possible Expansion (TGTX) - Seeking Alpha
(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
TG Therapeutics Experiences Evaluation Revision Amidst Evolving Market Dynamics - Markets Mojo
TG Therapeutics Q4 Earnings Call Highlights - MarketBeat
Q1 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):